Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

Zanganeh Mahkam

DUGGAN ROBERT W

Soni Manmeet Singh

Xia Yu

Founder SELLTHESPIKE CAFL Stockmarket Trading Investing  TrainTheEye Options Stocks Cars 97%biz/3% jokes Know your limit$ JDMBABroker Learn 2 think for yourself

Summit Therapeutics PLC (SMMT) Stock Price, Analysis & Trade Signals